MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,722.72
+0.73%
NASDAQ 100
$30,807.93
+1.00%
DOW JONES
$51,177.00
+0.49%
NASDAQ Composite
$27,190.86
+1.19%
RUSSELL 2000
$2,815.20
+0.90%
CBOE VIX
$15.31
-6.59%
Sector Heatmap
Technology+1.01%
Financials+0.06%
Healthcare-0.01%
Consumer Cycl+1.13%
Consumer Staples+0.25%
Energy+0.40%
Industrials+0.78%
Materials+0.66%
Real Estate+0.32%
Utilities+0.38%
Comm Services+0.35%
INMB — INmune Bio Inc. Common stock
NasdaqINmune Bio Inc. Common stock
$1.93
+0.00(+0.00%)
- O
- 1.97
- H
- 2.00
- L
- 1.93
- V
- 290.13K
⏱️ End-of-day dataAs of Oct 2, 2026
Chart
About INMB
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
SectorNot available
IPO DateFeb 4, 2019
Employees21
Stock ExchangeNasdaq
Ticker SymbolINMB
Websitehttps://www.inmunebio.com
Key Financial Statistics
| Market Cap | $53.56M |
| P/E Ratio | N/A |
| Dividend Yield | None |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $1.09 - $2.60 |
| 52-Week Avg Volume | 485.3K |
| VWAP | $1.96 |
| Transactions | 1,913 |
| Total Recorded Bars | 1,927 days |